Formulation and evaluation of effervescent tablets: a review by Patel, Salim G & Siddaiah, M
Patel et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2018; 8(6):296-303  
ISSN: 2250-1177                                                                                 [296]                                                                                  CODEN (USA): JDDTAO 
Available online on 15.11.2018 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits 
unrestricted non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                           Review Article 
Formulation and evaluation of effervescent tablets: a review 
Patel Salim G1*, Siddaiah M2 
1 Department of Pharmacy, Bhagwant University, Sikar Road, Ajmer, Rajasthan. India 
2 Jawaharlal Nehru Technological University ' Anantpuram, A.P., India 
 
ABSTRACT 
Oral dosage forms are the most popular way of taking medication, despite having some disadvantages compared with other 
methods like risk of slow absorption of the medicament, which can be overcome by administering the drug in liquid form, therefore, 
possibly allowing the use of a lower dosage. However, instability of many drugs in liquid dosage form limits its use. Effervescent 
technique can be used as alternate to develop a dosage form which can accelerate drug disintegration and dissolution, is usually 
applied in quick release preparations. Along with the development of new pharmaceutical technique, effervescent tablet are more 
and more extensively to adjust the behaviour of drug release, such as in sustained and controlled release preparations, pulsatile 
drug delivery systems, and so on. This review demonstrated the new applying of effervescent technique in effervescent tablets. 
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Oral drug delivery has been known for decades as the most 
widely utilized route of administered among all the routes 
that have been employed for the systemic delivery of drug 
via various pharmaceutical products of different dosage 
forms. The reasons that the oral route achieved such 
popularity may be in part attributed to its ease of 
administration.1-2 Oral sustained drug delivery system is 
complicated by limited gastric residence times (GRTs). 
Rapid GI transit can prevent complete drug release in the 
absorption zone and reduce the efficacy of the 
administered dose.3-4 
Effervescent tablets are becoming increasingly popular in a 
variety of sectors including supplements and 
pharmaceutical use due to the ease in which they can be 
consumed. Effervescent tablets are designed to break in 
contact with liquid such as water or juice, often causing 
the tablet to dissolve into a solution. 5 
These buoyant delivery systems utilize matrices prepared 
with swellable polymers such as Methocel or poly 
saccharides, e.g., chitosan, and effervescent components, 
e.g., sodium bicarbonate and citric or tartaric acid6 or 
matrices containing chambers of liquid that gasify at body 
temperature7-8. Flotation of a drug delivery system in the 
stomach can be achieved by incorporating a floating 
chamber filled with vacuum, air or an inert gas9.Gas can be 
introduced into the floating chamber by the volatilization 
of an organic solvent (e.g. Ether or cyclopentane) or by the 
CO2 produced as a result of an effervescent reaction 
between organic acids and carbonate–bicarbonate salts10. 
The matrices are fabricated so that upon arrival in the 
stomach, carbon dioxide is liberated by the acidity of the 
gastric contents and is entrapped in the jellified 
hydrocolloid. This produces an upward motion of the 
dosage form and maintains its buoyancy. A decrease in 
specific gravity causes the dosage form to float on the 
chyme11-12. Recently a multiple-unit type of floating pill, 
which generates carbon dioxide gas, has been developed. 
The system consisted of sustained- release pills as seeds 
surrounded by double layers. The inner layer was an 
effervescent layer containing both sodium bicarbonate and 
tartaric acid. The outer layer was a swellable membrane 
layer containing mainly polyvinyl acetate and purified 
shellac. Moreover, the effervescent layer was divided into 
two sub layers to avoid direct contact between sodium 
bicarbonate and tartaric acid. Sodium bicarbonate was 
contained in the inner sublayer and tartaric acid was in the 
outer layer. When the system was immersed in a buffer 
solution at 37°C, it sank at once in the solution and formed 
swollen pills, like balloons, with a density much lower than 
1 g/ ml. The reaction was due to carbon dioxide generated 
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by neutralization in the inner effervescent layers with the 
diffusion of water through the outer swellable membrane 
layers. The system was found to float completely within 10 
min and approximately 80%remained floating over a 
period of 5 hr irrespective of pH and viscosity of the test 
medium. While the system was floating, a drug (p-amino 
benzoic acid) was released. A variant of this approach 
utilizing citric acid (anhydrous) and sodium bicarbonate as 
effervescing agents and HPC-H grade as a release 
controlling agent has also been reported. In vitro results 
indicated a linear decrease in the FT of the tablets with an 
increase in the amount of effervescing agents in the range 
of 10–20%. Attempts have also been made to develop SR 
floating tablets using a mixture of sodium bicarbonate, 
citric acid and chitosan.13 
 
Figure 1: An effervescent tablet in a glass of water 
Effervescent or carbon tablets are tablets which are 
designed to dissolve in water, and release carbon 
dioxide.14-16 They are products of compression of 
component ingredients in the form of powders into a dense 
mass, which is packaged in blister pack, or with 
a hermetically sealed package with 
incorporated desiccant in the cap. To use them, they are 
dropped into water to make a solution. The powdered 
ingredients are also packaged and sold as effervescent 
powders or may be granulated and sold as effervescent 
granules. Generally powdered ingredients are first 
granulized before being made into tablets17-18  
Effervescent tablets are becoming increasingly popular in a 
variety of sectors including supplements and 
pharmaceutical use due to the ease in which they can be 
consumed. 
Effervescent tablets are designed to break in contact with 
liquid such as water or juice, often causing the tablet to 
dissolve into a solution. This makes effervescent tablets the 
preferred choice of many, including people who are taking 
tablets medicinally as well as a dietary supplement.19 
Here we look at 5 benefits of effervescent tablets 
over regular tablets. 20 
Pleasant Taste Compared to Regular Tablets 
Effervescent tablets are so popular due to the fact they can 
be dissolved in a liquid such as water or fruit juice, 
meaning that they often taste better than regular tablets. 
Conventional tablets dissolve slowly which can result in 
reduced absorption rates, effervescent tablets, in contrast, 
dissolve quickly and completely, meaning you get the full 
benefit from the ingredients. 
Distributed More Evenly 
Conventional tablets dissolve gradually in the stomach 
once ingested and can sometimes only partially dissolve 
which can lead to irritation in some cases. The benefit of 
effervescent tablets is that they dissolve completely and 
evenly meaning that localised concentrations of the 
ingredients cannot occur. This means not only a better 
taste but also less chance of irritation and a more efficient 
means of ingesting the ingredients. 
Increased Liquid Intake 
Effervescent tablets provide the nutritional benefits 
intended, but in addition to this they also increase liquid 
intake. This can be especially beneficial if you are 
dehydrated or ill and not ingesting as much fluid as 
usual. Effervescent tablets can be a fantastic way of 
rehydrating as well as reaping the benefits you are taking 
the tablets for whether this is a dietary supplement, 
herbally or medicinally. 
Easy Alternative to Regular Tablets 
They can be a great alternative for those who may have 
trouble swallowing either due to illness or age. Older 
individuals may have difficulty swallowing but need to take 
medication or supplements on a regular basis and in this 
respect, effervescent tablets can be a lot easier than having 
to swallow a tablet. In addition to this, they can be a great 
way of ingesting medicine for individuals with sore throats 
or medical issues that make swallowing difficult and so are 
a viable alternative to regular tablets. 
Simple and Easy to Measure 
Effervescent tablets are easily dissolved into water or a 
liquid of your choice and then after a while are consistent, 
well mixed and ready to drink. Traditional tablets or 
powders, however, need to be measured and stirred in 
repeatedly to avoid an inconsistent drink with lumpy bits. 
Even with stirring and measuring it is common to have an 
inconsistent drink with lumpy bits and an odd taste and 
this is where effervescent tablets are more efficient. Simply 
drop them in and they dissolve fully and evenly ensuring 
you get all the benefits of the tablet, as well as being able to 
comfortably drink it. 
To Sum Up 
Effervescent tablets are becoming increasingly popular and 
it is easy to see why. They provide a much more efficient 
way of taking supplements or medication due to being 
distributed evenly and much more quickly than regular 
tablets. In addition to this, they taste better as can be 
added to water or a liquid drink of your choice as well as 
being easier to take for people who may find it difficult to 
swallow. 
All these factors combine to make effervescent tablets a 
very popular choice for those taking tablets for either 
dietary supplementation or medicinal reasons. 
As per revised definition proposed to US FDA, Effervescent 
tablet is a tablet intended to be dissolved or dispersed in 
water before administration. Effervescent tablets are 
uncoated tablets that generally contain acid or acid salts 
(Citric, tartaric, Malic acid or any other suitable acid or acid 
anhydride) and carbonates or bicarbonates (Sodium, 
potassium or any other suitable alkali metal carbonate or 
hydrogen carbonate), which react rapidly in the presence 
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of water by releasing carbon dioxide. Due to liberation in 
CO2 gas, the dissolution of API in water as well as taste 
masking effect is enhanced. 16-20 
The reaction between Citric acid and Sodium bicarbonate 
& Tartaric acid and Sodium bicarbonate, which results in 
liberation of carbon dioxide shown as follows: 
C6H8O7.H2O+3NaHCO3 (aq) → Na3C6H5O7 + 4H2O + 3CO2 (g) ↑ 
Citric acid + Sodium bicarbonate → Sodium citrate + Water 
+ Carbon dioxide 
C4H6O6 + 2 NaHCO3→ Na2C4H4O6 + 2H2O + 2CO2 (g) ↑ 
Tartaric acid + Sodium bicarbonate → Sodium tartrate + 
Water + Carbon dioxide
 
 
Figure 2: Mechanism of Effervescence 
 
FUNDAMENTALS OF EFFERVESCENTS: 20-21 
Effervescence consists of a soluble organic acid and an 
alkali metal carbonate salt, one of which is often the API. 
Carbon dioxide is formed if this mixture comes into contact 
with water. Typical examples of the acids and alkalis used 
include: 
 Citric acid 
 Tartaric acid 
 Malic acid 
 Fumaric acid 
 Adipic acid 
 Sodium bicarbonate 
 Sodium carbonate 
 Sodium sesquicarbonate 
 Potassium bicarbonate 
 Potassium carbonate 
ADVANTAGES OF EFFERVESCENT TABLETS: 22-23 
 Fast onset of action. 
 No need to swallow tablet. 
 Good stomach and intestinal tolerance. 
 More portability. 
 Improved palatability. 
 Superior stability. 
 More consistent response. 
 Incorporation of large amounts of active ingredients. 
 Accurate Dosing. 
 Improved Therapeutic Effect. 
 In remote areas, especially where parenteral forms 
are not available due to prohibitive cost, lack of 
qualified medical staff, effervescent tablets could 
become an alternative. 
DISADVANTAGES OF EFFERVESCENT TABLETS: 22-23 
 Unpleasant taste of some active ingredients. 
 Larger tablets requiring special packaging materials. 
 Relatively expensive to produce due to large amount 
of more or less expensive excipients and special 
production facilities. 
 Clear solution is preferred for administration, 
although a fine dispersion is now universally 
acceptable. 
 
FORMULATION METHODOLOGIES: 24-36 
Wet Granulation:  
The most widely used process of agglomeration in 
pharmaceutical industry is wet granulation. Wet 
granulation process simply involves wet massing of the 
powder blend with a granulating liquid, wet sizing and 
drying.24-36 
Important steps involved in the wet granulation 
 Mixing of the drug(s) and excipients. 
 Preparation of binder solution. 
 Mixing of binder solution with powder mixture to 
form wet mass  
 Drying of moist granules. 
 Mixing of screened granules with disintegrant, glidant, 
and lubricant. 
Advantages 
 Permits mechanical handling of powders without loss 
of mix quality. 
 Improves the flow of powders by increasing particle 
size and sphericity. 
 Increases and improves the uniformity of powder 
density. 
Limitation of wet granulation 
 The greatest disadvantage of wet granulation is its 
cost. It is an expensive process because of labor, time, 
equipment, energy and space requirements. 
 Loss of material during various stages of processing. 
Dry Granulation:  
In dry granulation process the powder mixture is 
compressed without the use of heat and solvent. It is the 
least desirable of all methods of granulation. The two basic 
procedures are to form a compact of material by 
compression and then to mill the compact to obtain a 
granules. Two methods are used for dry granulation. The 
more widely used method is slugging, where the powder is 
recompressed and the resulting tablet or slug are milled to 
yield the granules. The other method is to recompress the 
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powder with pressure rolls using a machine such as 
Chilosonator.33-40 
Rollar Compaction:  
The compaction of powder by means of pressure roll can 
also be accomplished by a machine called chilsonator. 
Unlike tablet machine, the chilsonator turns out a 
compacted mass in a steady continuous flow. The powder 
is fed down between the rollers from the hopper which 
contains a spiral auger to feed the powder into the 
compaction zone. Like slugs, the aggregates are screened 
or milled for production into granules.40-43 
Use: Use in the production of directly compressible 
excipients, the compaction of drugs and drug formulations, 
the granulation of inorganic materials, the granulation of 
dry herbal material and the production of 
immediate/sustained release formulations. 
Advancement in Granulations 
Steam Granulation  
It is modification of wet granulation. Here steam is used as 
a binder instead of water. Its several benefits includes 
higher distribution uniformity, higher diffusion rate into 
powders, more favorable thermal balance] during drying 
step, steam granules are more spherical, have large surface 
area hence increased dissolution rate of the drug from 
granules, processing time is shorter therefore more 
number of tablets are produced per batch, compared to the 
use of organic solvent water vapour is environmentally 
friendly, no health hazards to operators, no restriction by 
ICH on traces left in the granules, freshly distilled steam is 
sterile and therefore the total count can be kept under 
control, lowers dissolution rate so can be used for 
preparation of taste masked granules without modifying 
availability of the drug.44-45 
Melt Granulation / Thermoplastic Granulation 
Here granulation is achieved by the addition of moldable 
binder. That is binder is in solid state at room temperature 
but melts in the temperature range of 50 – 80˚C. Melted 
binder then acts like a binding liquid. There is no need of 
drying phase since dried granules are obtained by cooling 
it to room temperature.46-48 
EVALUATION OF EFFERVESCENT TABLET 
Pre-compression parameters: 
1. Angle of repose (θ): 
Angle of repose is defined as the maximum angle possible 
between the surface of a pile of the powder and horizontal 
plane. The frictional force in a loose powder or granules 
can be measured by angle of repose. It is an indicative of 
the flow properties of the powder.49-50 
tan θ = H / R 
θ = tan-1 (H/R) 
Where, θ is the angle of repose 
H is height of pile 
R is radius of the base of pile 
The powder mixture was allowed to flow through the 
funnel fixed to a stand at definite height (H). The angle of 
repose was then calculated by measuring the height & 
radius of the heap of powder formed. Care was taken to see 
that the powder particles slip & roll over each other 
through the sides of the funnel. Relationship between angle 
of repose and powder flow property. 
Table 1: Angle of repose as an indication of powder flow 
properties 
Angle of repose (degrees) Type of flow 
< 20 Excellent 
20-30 Good 
30-34 Passable 
> 40 Very poor 
 
2. Flow Rate: 
Flow rate of a powder has been defined as the rate at 
which the particular mass emerges through the office of 
funnel of a suitable diameter. The flow rate for granules of 
each formulation was determined by pouring accurately 
weighed quantities of granules in funnel with an orifice of 
8 mm diameter. The time required for the complete 
granule mass to emerge out of the orifice was recorded 
using a stopwatch. The flow rate was calculated from 
following equation: 49 
          
                  
               
 
3. Bulk Density: 
The bulk density was obtained by dividing the mass of a 
powder by the bulk volume in cm3. The sample of about 50 
cm3 of powder, previously been passed through a standard 
sieve no. 20, was carefully introduced into a 100 ml 
graduated cylinder. The cylinder was dropped at 2-second 
intervals onto a hard wood surface three times from a 
height of 1 inch. The bulk density of each formulation was 
then obtained by dividing the weight of sample in grams by 
the final volume in cm3 of the sample contained in the 
cylinder. It was calculated by using equation below:49 
Df = M/Vp 
Where  
Df = bulk density  
M = weight of samples in grams  
Vp = final volumes of granules in cm3 
4. Tapped density:  
The tapped density was obtained by dividing the mass of a 
powder by the tapped volume in cm3. The sample of about 
50 cm3 of powder previously been passed through a 
standard sieve no. 20, is carefully introduced into a 100 ml 
graduated cylinder. The cylinder was dropped at 2-second 
intervals onto a hard wood surface 100 times from a height 
of 1 inch. The tapped density of each formulation was then 
obtained by dividing the weight of sample in grams by the 
final tapped volume in cm3 of the sample contained in the 
cylinder. It was calculated by using equation given below:  
Do= M/Vp 
Where  
Do= bulk density  
M = weight of samples in grams  
Vp = final volumes of granules in cm3 
5. Carr’s Index:  
An indirect method of measuring powder flow from bulk 
densities was developed by Carr. The percentage 
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compressibility of a powder was a direct measure of the 
potential powder arch or bridge strength and stability. 
Carr’s index of each formulation was calculated according 
to equation given below: 
                    
      
  
      
Where, 
Df = Fluff or Poured bulk or bulk density. 
Do = Tapped or Consolidated bulk density.  
 
Table 2: Carr’s Index as an indication of powder flow 
Carr’s index (%) Type of flow 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
Evaluation of Effervescent tablets  
Weight variation: Weight variation was determined to 
know whether different batches of tablets have uniformity. 
Weighed 20 tablets individually, calculated the average 
weight and compared the individual tablet weights to the 
average. The tablets meet the test if not more than two 
tablets are outside the % limit and none of the tablet differ 
by more than two times the % limit. Weight variation 
specification as per I.P. is shown in table no.6.18. 
Table: 3: Weight variation specification. 
IP/BP Limit USP 
80 mg or less 10% 130mg or less 
More than 80mg or 
Less than 250mg 
7.5% 130mg to 324mg 
250mg or more 5% More than 324mg 
 
Tablet Thickness and Diameter: 
Thickness and diameter of tablets were important for 
uniformity of tablet size. Thickness and diameter were 
measured using Vernier Calipers.  
Tablet Hardness: 
The resistance of tablets to shipping or breakage under 
conditions of storage, transportation and handling before 
usage depends on its hardness. The hardness of tablet of 
each formulation was measured by Monsanto Hardness 
Tester. The hardness was measured in items of kg/cm2. 
Hardness or tablet crushing strength is the force required 
to break a tablet in a diametric compression. The force is 
measured in kg and the hardness of about 3-5 kg/cm2 is 
considered to be satisfactory for uncoated tablets.  
Friability (F):  
Friability of the tablet determined using Roche friabilator. 
This device subjects the tablet to the combined effect of 
abrasion and shock in a plastic chamber revolving at 25 
rpm and dropping a tablet at a height of 6 inches in each 
revolution. Pre weighted sample of tablets was placed in 
the friabilator and were subjected to the 100 revolutions. 
Tablets were dusted using a soft muslin cloth and 
reweighed. USP limit is 0.5 to 1%. The friability (F) is given 
by the formula 
   
                  
         
      
Measurement of effervescence time  
A single tablet is placed in a beaker containing 200 ml of 
purified water at 20 °C ± 1 °C. Whenever a clear solution 
without particles is obtained effervescence time has 
finished. 
The mean of three measurements of each formulation is to 
be reported. 
Determination of effervescent solution pH  
pH of solution is determined with one tablet in 200 ml of 
purified water at 20 ± 1 °C by using pH meter, immediately 
after completing the dissolution time.  Repeat experiment 
3times for each formulation. 
Measurement of CO2 content  
One effervescent tablet solved in 100 ml of 1N sulphuric 
acid solution and weight changes were determined after 
dissolution end. The obtained weight difference is shown 
the amount (mg) of CO2 per tablet. Reports the averages of 
3determinations. 
Evaluation of the water content  
10 tablets of each formulation are dried in a desiccators 
containing of activated silica gel for 4 hours. Water content 
of 0.5% or less is acceptable. 
Uniformity of Content:  
10 tablets were selected randomly. Each tablet was 
transferred into a 50mL volumetric flask, dissolved and 
diluted to 50 mL with phosphate buffer pH 6.8. One ml of 
this solution was diluted to 100 ml with phosphate buffer 
pH 6.8. The amount of drug present in each tablet was 
determined by UV spectroscopy at 246 nm. Standard limit 
for uniformity of content is 
IP: - Active less than 10mg or 10%, 
BP:- Active less than 2 mg or 2%, 
USP:- Active less than 25mg or 25%. 
 10 tabs limit NMT 1 tab deviate 85 – 115% & none 
outside 75 – 125% of the Avg value/IP/BP/USP 
(Relative Standard Deviation less than or equal to 
6%), 
 If 2 or 3 individual values are outside the limits 85 – 
115% of the Avg value, & none outside 75 – 125% 
repeat for 20 tablets. 
Determination of the equilibrium moisture content  
Three desiccators are prepared containing saturated salt 
solutions of potassium nitrate (for creation 90% RH, at 18 
°C), sodium chloride (for creation 71% RH, at 18 °C) and 
sodium nitrite (for creation 60% RH, at 18 °C). Three 
tablets of each formulation are placed in desiccators. Then, 
the equilibrium moisture content is determined by Karl 
Fischer method and the autotitrator device in the first day 
and after 7day. 
In-vitro disintegration time 
The process of breakdown of a tablet into smaller particles 
is called as disintegration. The in-vitro disintegration time 
of a tablet was determined using disintegration test 
apparatus as per I.P. specifications. 
I.P. Specifications: Place one tablet in each of the 6 tubes of 
the basket. Add a disc to each tube and run the apparatus 
using phosphate buffer (pH-6.8) maintained at37°±2°C as 
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the immersion liquid. The assembly should be raised and 
lowered between 30 cycles per minute in the phosphate 
buffer (pH-6.8) maintained at 37°±2°C. The time in seconds 
taken for complete disintegration of the tablet with no 
palpable mass remaining in the apparatus was measured 
and recorded. Standard limit for disintegration time is 
within 3 min in water at 250C ± 10C (IP) and 15 – 250C 
(BP). The results are given in table no.6.27. 
Dissolution Studies  
The release rate of Atorvastatin from mouth dissolving 
tablets was determined using USP Dissolution Testing 
Apparatus II (Paddle type). The dissolution medium used 
was 900 ml of phosphate buffer pH 6.8 which was 
maintained at 37±0.50C. The paddle speed was kept at 50 
rpm throughout the study. Five ml of samples was 
withdrawn at every 5 minutes interval and diluted to 10ml 
then 5ml of fresh dissolution media maintained at the same 
temperature was replaniced. The samples were analysed 
spectrophotometrically at 246nm using phosphate buffer 
pH 6.8 as blank. The raw dissolution data was analyzed for 
calculating the amount of drug released and percentage 
cumulative drug released at different time intervals.  
Release Kinetic Modeling: 22, 23, 25, 41, 49, 50 
In recent years, drug release from pharmaceutical dosage 
forms has been the subject of intense and profitable 
scientific developments. Whenever a new dosage form is 
developed form is developed, it is it is necessary to ensure 
that drug release occurs in an appropriate manner. The 
quantitative analysis of the values obtained in release tests 
is easier when mathematical formulas that express the 
release results as a function of some of the dosage forms 
characteristics are used. In some cases, these mathematic 
models are derived from the theoretical analysis of the 
occurring process. Drug dissolution from dosage forms has 
been described by kinetic models in which the dissolved 
amount of drug (Q) is a function of the test time, t or Q=f 
(t). Some analytical definitions of the Q (t) function are 
commonly used, such as zero order, first order, Higuchi 
and Korsmeyer–Papas. 
In-vitro dissolution has been recognized as an important 
pharmaceutical dosage form can influence the release 
element in drug development. Under certain conditions it 
kinetic be used as a surrogate for the assessment of 
bioequivalence. Several theories / kinetics models describe 
drug dissolution from immediate and modified release 
dosage forms. There are several models to represent the 
drug dissolution profiles where ft is a function of t (time) 
related to the amount of drug dissolved from the 
pharmaceutical dosage system. In most cases, with tablets, 
capsules, coated forms or prolonged release forms that 
theoretical fundament does not exist and sometimes a 
more adequate empirical equations used. A water-soluble 
drug incorporated in a matrix is mainly released by 
diffusion, while for a low water-soluble drug the self-
erosion of the matrix will be the principal release 
mechanism. To accomplish these studies the cumulative 
profiles of the dissolved drug are t more commonly used in 
opposition to their differential profiles. To compare 
dissolution profiles between two drug products model 
dependent (curve fitting), statistical analysis and model 
independent methods can be used. 
Zero order kinetics: 
Drug dissolution from dosage forms that do not 
disaggregate and release the drug slowly can be 
represented by the following equation 
Wo-Wt= Kt 
Where, 
Wo  is the initial amount of drug in the dosage 
form. 
Wt  is the initial amount of drug in the dosage 
form at time( t) 
K is the proportionality constant. 
Dividing this equation by and simplify 
Ft=Kot 
Where ft= 1-(Wt-Wo) and ft represents the fraction of drug 
dissolved in time t and Ko the zero order of release 
constant. 
This relation can be used to describe the modified release 
dosage form; the following relation can, in simple way to 
express this model 
Qt = Qo + Kot 
Where, 
Qt is the amount of drug dissolved in time t. 
Qo is the amount of drug in the solution. 
First order kinetics: 
Gibaldi and Feldman first proposed the application of this 
model to drug dissolution studies in 1967 and later by 
Wagner in 1969. The dissolution phenomena of solid 
particles in a liquid media implies a surface action, as can 
be seen by the Noyes- Whitney equation. 
DC/dt= K (Cs-C) 
Where, 
C is the concentration of the solute in time t 
Cs is the solubility in the equilibrium at 
expression temperature  
K is the first order proportionality 
Higuchi model: 
Higuchi developed several theoretical models to study the 
release of water soluble and low soluble drops 
incorporated in the matrixes. The drug particles dispersed 
in a uniform matrix behaving as the diffusion media, the 
relation obtained was the following: 
ft = Q=D(2C-Cs) Cst 
Where, 
Q is the amount of drug released in time t, per 
unit area,  
C is the drug initial concentration, 
Cs is the drug solubility in the matrix media. 
D is the diffusivity of the drug molecules 
(diffusion constant in matrix). 
dQ = Cdh – ½ (Csdh) 
but, in accordance to the first law (dq/dt = DC/h) 
Higuchi in 1962 proposed the following equation, for the 
case in which the drug is dissolution. 
In general way it is possible to resume the Highuchi model 
to the following expression (generally known as the 
simplified Higuchi model). 
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Ft = KHt1/2. 
Where KH is the Highuchi dissolution constant treated 
sometimes in a different manner by different authors and 
theories. Higuchi describes drug release as a diffusion 
process based on Fick’s law, square root time dependent. 
Korsmeyer – Peppas model: 
Korsmeyer et al., in 1983 was developed a simple, semi 
empirical model, relating exponentially the drug release to 
the elapsed time (t). 
ft = atn 
a – is a constant incorporating structural and geometric 
characteristics of the drug dosage from, n is the release 
exponent, indicate of the drug release mechanisms and the 
functions of t is Mt/M (Fractional release of drug). If drug 
release occurs under perfect sink condition, the following 
initial and boundary conditions, the following initial and 
boundary conditions can be assumed. 
t=0-d/2<x<d/z            C =C0 
t>0.   x=  d/z                              C =C1 
C0-is the initial drug concentration in the device. 
C1 -is the concentration of drug at the polymer water 
interface. 
In the diffusion is the main drug release mechanism, a 
graphic representation the drug amount released, in the 
referred conditions, versus the square root of time should 
originate a straight line. 
Table 4: Mathematical models used to describe drug 
release mechanism. 
S. No. Mathematical model Equation 
1. Zero order Qt = Qo + Kot 
2. First order ln Q = ln Qo + K1t 
3. Higuchi Qt=KH√t 
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